<p>Tepmetko is a cancer medicine that is used to treat adults with non-small cell lung cancer (NSCLC) when the cancer is advanced and its cells have particular genetic mutations (changes) leading to ‘mesenchymal-epithelial transition factor gene exon 14’ (METex14) skipping. This means that the cancer cells make an abnormal form of a protein called MET because a part of the MET gene known as exon 14 is not used.</p><p>Tepmetko is used when the patient needs further treatment after receiving immunotherapy or platinum-based chemotherapy, or both.</p><p>Tepmetko contains the active substance tepotinib.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.</p> </div>
Therapeutic Area (MeSH)
ATC Code
L01EX21
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| tepotinib hydrochloride monohydrate | N/A | tepotinib hydrochloride monohydrate |
EMA Name
Tepmetko
Medicine Name
Tepmetko
Aliases
N/ANo risk management plan link.
